Pneumo News

, Volume 10, Issue 2, pp 31–40 | Cite as

Genetische Ursache einer COPD

Alpha-1-Antitrypsin-Mangel: Pathophysiologie, Diagnostik und Therapie

  • Sebastian Fähndrich
  • Nikolas Bernhard
  • Philipp Lepper
  • Robert Bals
cme fortbildung
First Online:
  • 2 Downloads

Zusammenfassung

Die chronisch obstruktive Lungenerkrankung (COPD) ist eine durch inhalative Noxen hervorgerufene chronische Erkrankung, deren Phänotyp neben Umwelteinflüssen auch durch genetische Ursachen wie einem Alpha-1-Antitrypsin(AAT)-Mangel beeinflusst wird, eine Genotypisierung kann mittels Polymerasekettenreaktion und Sequenzierung erfolgen. Um eine Progression der Erkrankung zu verlangsamen, kann AAT substituiert werden.

This is a preview of subscription content, log in to check access

Literatur

  1. 1.
  2. 2.
    Laurell CB, Eriksson S. The electrophoretic alpha1-globulin pattern of serum in alpha1-antitrypsin deficiency. 1963. COPD. 2013;10 Suppl 1:3–8CrossRefGoogle Scholar
  3. 3.
    Konietzko N. [How Carl-Bertil Laurell and Sten Eriksson detected the alpha-1-antitrypsin deficiency 50 years ago and what then came—a somewhat headstrong and personal retrospection]. Pneumologie. 2013;67(10):562–6CrossRefGoogle Scholar
  4. 4.
    Blanco I, de Serres FJ, Fernandez-Bustillo E et al. Estimated numbers and prevalence of PI*S and PI*Z alleles of alpha1-antitrypsin deficiency in European countries. Eur Respir J. 2006;27(1):77–84CrossRefGoogle Scholar
  5. 5.
    Lomas DA, and Parfrey H. Alpha1-antitrypsin deficiency. 4: Molecular pathophysiology. Thorax. 2004;59(6):529–35CrossRefGoogle Scholar
  6. 6.
    Greene CM, McElvaney NG. Z alpha-1 antitrypsin deficiency and the endoplasmic reticulum stress response. World J Gastrointest Pharmacol Ther. 2010;1(5):94–101CrossRefGoogle Scholar
  7. 7.
    Fairbanks KD, Tavill AS. Liver disease in alpha 1-antitrypsin deficiency: a review. Am J Gastroenterol. 2008;103(8):2136–41; quiz 42CrossRefGoogle Scholar
  8. 8.
    Kamimoto T, Shoji S, Hidvegi T et al. Intracellular inclusions containing mutant alpha1-antitrypsin Z are propagated in the absence of autophagic activity. J Biol Chem. 2006;281(7):4467–76CrossRefGoogle Scholar
  9. 9.
    Hidvegi T, Mirnics K, Hale P et al. Regulator of G Signaling 16 is a marker for the distinct endoplasmic reticulum stress state associated with aggregated mutant alpha1-antitrypsin Z in the classical form of alpha1-antitrypsin deficiency. J Biol Chem. 2007;282(38):27769–80CrossRefGoogle Scholar
  10. 10.
    Perlmutter DH. Clinical manifestations of alpha 1-antitrypsin deficiency. Gastroenterol Clin North Am. 1995;24(1):27–43PubMedGoogle Scholar
  11. 11.
    Campbell EJ, Campbell MA, Boukedes SS et al. Quantum proteolysis by neutrophils: implications for pulmonary emphysema in alpha 1-antitrypsin deficiency. J Clin Invest. 1999;104(3):337–44CrossRefGoogle Scholar
  12. 12.
    Stockley RA. Alpha 1-antitrypsin: more than just deficiency. Thorax. 2004;59(5):363–4CrossRefGoogle Scholar
  13. 13.
    DeMeo DL, Silverman EK. Alpha1-antitrypsin deficiency. 2: genetic aspects of alpha(1)-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk. Thorax. 2004;59(3):259–64CrossRefGoogle Scholar
  14. 14.
    Needham M, Stockley RA. Alpha 1-antitrypsin deficiency. 3: Clinical manifestations and natural history. Thorax. 2004;59(5):441–5CrossRefGoogle Scholar
  15. 15.
    Hersh CP, Dahl M, Ly NP et al. Chronic obstructive pulmonary disease in alpha1-antitrypsin PI MZ heterozygotes: a meta-analysis. Thorax. 2004;59(10):843–9CrossRefGoogle Scholar
  16. 16.
    Brantly ML, Paul LD, Miller BH et al. Clinical features and history of the destructive lung disease associated with alpha-1-antitrypsin deficiency of adults with pulmonary symptoms. Am Rev Respir Dis. 1988;138(2):327–36CrossRefGoogle Scholar
  17. 17.
    Carrell RW, Lomas DA. Alpha1-antitrypsin deficiency—a model for conformational diseases. N Engl J Med. 2002;346(1):45–53CrossRefGoogle Scholar
  18. 18.
    Stoller JK, Snider GL, Brantly ML et al. [American Thoracic Society/European Respiratory Society Statement: Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency]. Pneumologie. 2005;59(1):36–68CrossRefGoogle Scholar
  19. 19.
    Silverman EK, Sandhaus RA. Clinical practice. Alpha1-antitrypsin deficiency. N Engl J Med. 2009;360(26):2749–57CrossRefGoogle Scholar
  20. 20.
    Eriksson S, Carlson J, Velez R. Risk of cirrhosis and primary liver cancer in alpha 1-antitrypsin deficiency. N Engl J Med. 1986;314(12):736–9.CrossRefGoogle Scholar
  21. 21.
    Nelson DR, Teckman J, Di Bisceglie AM et al. Diagnosis and management of patients with alpha1-antitrypsin (A1AT) deficiency. Clin Gastroenterol Hepatol. 2012;10(6):575–80CrossRefGoogle Scholar
  22. 22.
    Bowlus CL, Willner I, Zern MA et al. Factors associated with advanced liver disease in adults with alpha1-antitrypsin deficiency. Clin Gastroenterol Hepatol. 2005;3(4):390–6CrossRefGoogle Scholar
  23. 23.
    Silverman EK, Pierce JA, Province MA et al. Variability of pulmonary function in alpha-1-antitrypsin deficiency: clinical correlates. Ann Intern Med. 1989;111(12):982–91CrossRefGoogle Scholar
  24. 24.
    Seersholm N, Kok-Jensen A, Dirksen A. Survival of patients with severe alpha 1-antitrypsin deficiency with special reference to non-index cases. Thorax. 1994;49(7):695–8CrossRefGoogle Scholar
  25. 25.
    Parr DG, Stoel BC, Stolk J et al. Pattern of emphysema distribution in alpha1-antitrypsin deficiency influences lung function impairment. Am J Respir Crit Care Med. 2004;170(11):1172–8CrossRefGoogle Scholar
  26. 26.
    Gross B, Grebe M, Wencker M et al. New Findings in PiZZ alpha1-antitrypsin deficiency-related panniculitis. Demonstration of skin polymers and high dosing requirements of intravenous augmentation therapy. Dermatology. 2009;218(4):370–5CrossRefGoogle Scholar
  27. 27.
    Mahr AD, Edberg JC, Stone JH et al. Alpha(1)-antitrypsin deficiency-related alleles Z and S and the risk of Wegener’s granulomatosis. Arthritis Rheum. 2010;62(12):3760–7CrossRefGoogle Scholar
  28. 28.
    Stoller JK, Sandhaus RA, Turino G et al. Delay in diagnosis of alpha1-antitrypsin deficiency: a continuing problem. Chest. 2005;128(4):1989–94CrossRefGoogle Scholar
  29. 29.
    Greulich T, Ottaviani S, Bals R et al. Alpha1-antitrypsin deficiency - diagnostic testing and disease awareness in Germany and Italy. Respir Med. 2013;107(9):1400–8CrossRefGoogle Scholar
  30. 30.
    American Thoracic S, European Respiratory S. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168(7):818–900CrossRefGoogle Scholar
  31. 31.
    Bostrom S, Nilsson I. Telescopic suction tube for microsurgery. Acta Neurochir (Wien). 1992;118(3-4):162–3CrossRefGoogle Scholar
  32. 32.
    Costa X, Jardi R, Rodriguez F et al. Simple method for alpha1-antitrypsin deficiency screening by use of dried blood spot specimens. Eur Respir J. 2000;15(6):1111–5CrossRefGoogle Scholar
  33. 33.
    McElvaney NG, Burdon J, Holmes M et al. Long-term efficacy and safety of a1 proteinase inhibitor treatment for emphysema caused by severe a1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE). Lancet Respir Med. 2017 Jan;5(1):51–60CrossRefGoogle Scholar
  34. 34.
    Stoller JK, Aboussouan LS. Alpha1-antitrypsin deficiency. Lancet. 2005;365(9478):2225–36CrossRefGoogle Scholar
  35. 35.
    Crystal RG. Alpha 1-antitrypsin deficiency, emphysema, and liver disease. Genetic basis and strategies for therapy. J Clin Invest. 1990;85(5):1343–52CrossRefGoogle Scholar
  36. 36.
    Ferrarotti I, Thun GA, Zorzetto M et al. Serum levels and genotype distribution of alpha1-antitrypsin in the general population. Thorax. 2012;67(8):669–74CrossRefGoogle Scholar
  37. 37.
    Wewers MD, Casolaro MA, Sellers SE et al. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med. 1987;316(17):1055–62CrossRefGoogle Scholar
  38. 38.
    Stoller JK, Aboussouan LS. alpha1-Antitrypsin deficiency. 5: intravenous augmentation therapy: current understanding. Thorax. 2004;59(8):708–12CrossRefGoogle Scholar
  39. 39.
    Seersholm N, Wencker M, Banik N et al. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. Eur Respir J. 1997;10(10):2260–3CrossRefGoogle Scholar
  40. 40.
    Tomashefski JF Jr., Crystal RG, Wiedemann HP et al. The bronchopulmonary pathology of alpha-1 antitrypsin (AAT) deficiency: findings of the Death Review Committee of the national registry for individuals with Severe Deficiency of Alpha-1 Antitrypsin. Hum Pathol. 2004;35(12):1452–61CrossRefGoogle Scholar
  41. 41.
    Wencker M, Fuhrmann B, Banik N et al. Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor. Chest. 2001;119(3):737–44CrossRefGoogle Scholar
  42. 42.
    Chapman KR, Stockley RA, Dawkins C et al. Augmentation therapy for alpha1 antitrypsin deficiency: a meta-analysis. COPD. 2009;6(3):177–84CrossRefGoogle Scholar
  43. 43.
    Dowson LJ, Guest PJ, Hill SL et al. High-resolution computed tomography scanning in alpha1-antitrypsin deficiency: relationship to lung function and health status. Eur Respir J. 2001;17(6):1097–104CrossRefGoogle Scholar
  44. 44.
    Dawkins PA, Dowson LJ, Guest PJ et al. Predictors of mortality in alpha1-antitrypsin deficiency. Thorax. 2003;58(12):1020–6CrossRefGoogle Scholar
  45. 45.
    Dirksen A, Dijkman JH, Madsen F et al. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med. 1999;160(5 Pt 1):1468–72CrossRefGoogle Scholar
  46. 46.
    Dirksen A, Piitulainen E, Parr DG et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency. Eur Respir J. 2009;33(6):1345–53CrossRefGoogle Scholar
  47. 47.
    Chapman KR, Burdon JG, Piitulainen E et al. Intravenous augmentation treatment and lung density in severe alpha1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;386(9991):360–8CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  • Sebastian Fähndrich
    • 1
  • Nikolas Bernhard
    • 1
  • Philipp Lepper
    • 1
  • Robert Bals
    • 1
  1. 1.Klinik für Innere Medizin V - Pneumologie, Allergologie, Beatmungs- und UmweltmedizinUniversitätsklinikum des SaarlandesHomburg/SaarDeutschland

Personalised recommendations